索拉菲尼对人肝癌细胞株HepG2抑制作用的研究  

DEPRESSANT EFFECTS OF SORAFENIB ON HUMAN LIVER CANCER CELL LINE HEPG2

作　　者：孙同友[1] 李青山[2] 孙立新[2] 刑恩鸿[2] 梁秀军[1] 

机构地区：[1]承德医学院,河北承德067000 [2]承德医学院附属医院

出　　处：《承德医学院学报》2009年第3期241-243,共3页Journal of Chengde Medical University

摘　　要：目的:探讨分子靶向药物索拉菲尼(Sorafenib)在体外对人肝癌细胞株HepG2的抑制作用。方法:采用MTT法检测Sorafenib对HepG2细胞的增殖抑制率,流式细胞仪分析细胞周期和凋亡率。结果:Sorafenib能明显抑制HepG2细胞增殖,呈时间-剂量依赖效应;6μmol/L的Sorafenib处理HepG2细胞72小时,HepG2细胞周期中的S期比例明显升高,G0-G1期、G2-M期比例明显下降,凋亡率明显上升(P<0.05,P<0.01)。结论:Sorafenib对体外人肝癌HepG2细胞具有明显的抑制作用,主要表现为抑制其增殖和促进其凋亡。Objective：To investigate the depressant effects of Sorafenib on human liver cancer cell line HepG2 cells in vitro.Methods：MTT method was used to detect the antiproliferative ratio of Sorafenib on HepG2 cells, flow cytometry to analyze the cell cycle and apoptotic ratio.Results：Sorafenib could obviously inhibit proliferation of HepG2 cells and appeared time-dose-dependent effects.72 hours after the HepG2 cells were treated with Sorafenib in 6 μmol/L, the percentage of HepG2 ceils in S period increased, G0-G1 period and G2-M period HepG2 cells decreased, aopototic ratio of HepG2 cells increased significantly （P〈0.05, P〈0.01）. Conclusions：Sorafenib can inhibit proliferation and promote apoptosis of human liver cancer cell line HepG2 cells in vitro.

关 键 词：索拉菲尼 人肝癌细胞株HEPG2 MTT法 流式细胞术 

分 类 号：R735.7[医药卫生—肿瘤]